Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 20, 2014, 07:01:39 AM

Login with username, password and session length


Members
  • Total Members: 23730
  • Latest: lume
Stats
  • Total Posts: 642741
  • Total Topics: 48891
  • Online Today: 183
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 4
Guests: 153
Total: 157

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: iHIVARNA(Therapeutic TriMix/mRNA based Vaccine in ChronicHIV-1 Infected Patients  (Read 860 times)

0 Members and 1 Guest are viewing this topic.

Offline Matts

  • Member
  • Posts: 223
http://cordis.europa.eu/projects/rcn/110278_en.html

http://blog.hospitalclinic.org/en/2013/12/projecte-ihivarna-vacuna-terapeutica-sida-idibaps/#more-13646

"EU Grants a Project to Test an Innovative HIV Vaccine Candidate in two phase I/IIa clinical trials

The four-year 6M€ European project iHIVARNA, funded by the European Commission, aims to successfully immunize antiretroviral-treated HIV-infected patients with 3 injections of the candidate universal HIV-TriMix-mRNA as an mRNA-based therapeutic vaccine with the final aim of improving the efficacy of therapeutic vaccination against HIV infection.

iHIVARNA is addressing the topic “Safety and efficacy of therapeutic vaccines” of the European Commission 7th Framework Programme Health 2013. The project brings together the expertise of a number of European groups (Spain, Belgium, and Netherlands) in dendritic cell targeting, rational design of immunogens, mRNA manufacturing and immuno-virological monitoring. This proposal continues the work in therapeutic vaccines performed in the last few years in the AIDS Research Unit of IDIBAPS leaded by Dr. Josep M Gatell and the Institute for AIDS Research IrsiCaixa. Dr. Felipe García, from IDIBAPS, is the coordinator of the iHIVARNA Consortium.

Dr. Josep M Gatell said: “Nowadays, over 30 million people worldwide are infected with HIV, most of them living in developing countries. Although combined antiretroviral therapy (cART) has proven to be highly effective to prevent clinical progression and death, by itself it is unable to eradicate the infection and other alternative approaches are urgently needed”. The consortium coordinator Dr. Felipe García, from IDIBAPS said: “Therapeutic vaccinations – vaccines targeting HIV infected patients with the ultimate aim of achieving a functional cure – have emerged as one of the most promising strategies that could restore HIV-specific T-cell responses in HIV infected patients and help them control viral replication without cART. Our novel therapeutic vaccine candidate is going to be tested for the first time in two phase I and phase IIa clinical trials to assess if it is a valid alternative to lifelong cART treatment.”

The iHIVARNA vaccine candidate is the result of a long lasting scientific track record of the Consortium. The candidate is based on an innovative approach that uses naked mRNA, so far has only been recently applied in the cancer research field. The HIV-TriMix-mRNA has two parts: HIV that has been rationally designed by IrsiCaixa based on data from large international cohorts; and TriMix designed by Vrije Universiteit Brussel to activate and target dendritic cells to improve the HIV antigen presentation. The combination of mRNA, rationally designed HIV antigen and TriMix is a very innovative approach for a therapeutic vaccine and is expected to improve the results of other more traditional strategies already tested.

Studies included in iHIVARNA comprise 1) the manufacturing of the HIV-TriMix-mRNA in GMP conditions, 2) a phase I dose escalation clinical trial and a phase IIa-proof-of-concept clinical trial to test safety, efficacy and immunogenicity of the vaccine candidate, and 3) ascertaining immune and viral predictors and correlates of protection.

Project Information:
The iHIVARNA project (full title: Therapeutic TriMIx / mRNA based Vaccine in Chronic HIV-1 Infected Patients on Antiretroviral Therapy) is funded with approximately 6 million Euro granted by the European Commission in the 7th Framework Programme, coordinated by Dr. Felipe García of IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer) and carried out by 8 leading research institutions and SMEs.

iHIVARNA started the 1st December 2013, with a duration of 48 months.

The full list of participating institutions is:

•Consorcio Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
•Instituut voor Tropische Geneeskunde (ITM)
•Vrije Universiteit Brussel (VUB)
•eTheRNA BVBA (eTheRNA)
•Erasmus Universitair Medisch Centrum Rotterdam (EMC)
•Instituto de Investigación del Sida IrsiCaixa
•Synapse Research Management Partners S.L. (SYNAPSE)
•Asphalion, S.L. (ASPHALION) "
tivicay/kivexa

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.